Our research aim is to develop clinical engineering tools for the diagnosis and treatment of pathologies in which biomechanics is an important contributing factor (e.g. myopia, glaucoma, atherosclerosis, aneurysms, and osteoarthritis). The translational nature of our work requires close collaboration with clinicians and industry, which we have fostered in past years and will continue to expand. Our research can make a significant positive impact on the quality of life of patients while delivering economic benefits. We strongly believe that such an aim can only be achieved by a research group with extensive expertise in a wide range of domains, which we intend to expand at the National University of Singapore.
We believe that we can achieve personalised medicine for pathologies in which biomechanics is an important contributing factor. We also believe that it is now crucial to quantify the biomechanics of tissues in vivo. We are currently developing state-of-the-art tools to achieve this.
Upon knowledge of in vivo biomechanics, we will be able to diagnose multiple disorders together with the help of patient specific biomechanical models. In vivo biomechanics can also drive the development of novel surgical procedure and novel medical devices for the treatment of biomechanical disorders.
Our goal is to bring biomechanical tools to the clinic and make them widely available for clinicians to significantly improve our current healthcare system. Developing biomechanical tools for the clinic does not go without quantification of biomechanics ex-vivo and using animal disease models. This latter aspect is also a strong component of our laboratory.